Design, synthesis, and biological evaluation of a small molecule oral agonist of the glucagon-like-peptide-1 receptor

Novel approaches to the treatment of type 1 diabetes

“… 19 A small molecule glucagon‐like peptide 1 receptor agonist is also being studied as a potential agent to reduce pancreatic β‐cell apoptosis and dysfunction. 20 …”

“…A small molecule plant alkaloid derived from L‐tryptophan, harmine, is one such DYRK1A inhibitor, investigated in the past for central nervous system effects and now being considered as an agent to increase endogenous insulin secretory capacity 19 . A small molecule glucagon‐like peptide 1 receptor agonist is also being studied as a potential agent to reduce pancreatic β‐cell apoptosis and dysfunction 20 …”

“…19 A small molecule glucagon-like peptide 1 receptor agonist is also being studied as a potential agent to reduce pancreatic β-cell apoptosis and dysfunction. 20 Thus, it appears that a number of lines of investigation suggest approaches that may prove of benefit in the treatment of early T1D. It is intriguing to speculate that some of these agents may be effective in combination, with, for example, both verapamil and harmine altering cytoplasmic ionized calcium levels or with combination of a pro-proliferative agent one reducing β-cell autoimmunity.…”